Celldex Therapeutics inc (CLDX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CLDX Annual Balance Sheets →
The table below presents a historical view of Celldex Therapeutics inc's balance sheet, supporting analysis of financial position trends.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent35.73
Marketable Securities, Current SH415.73
Cash & Short-term Investments450.00
Accounts receivable0.23
Prepaid Expense And Other Assets Current7.53
Total Current Assets459.22
Equipment/Property/Plant Net7.40
Intangible Assets27.19
Other Assets, Noncurrent17.45
Operating Lease Right Of Use Asset2.01
Total Assets511.25
Liabilities
Accounts Payable, Current AC10.36
Accrued Liabilities, Current AC38.42
Other Liabilities, Current2.70
Total Current Liabilities51.47
Total Long-term Debt0.00
Other liabilities, Noncurrent3.56
Operating Lease Liability Current1.47
Operating Lease Liability Noncurrent0.44
Total Liabilities55.03
Stockholders' Equity
Common Stock Value0.07
Additional Paid In Capital Common Stock2,346.30
Retained Earnings / Accumulated Deficit-1,892.67
Other Equity2.52
Common Stockholder's Equity456.23
Total Stockholder's Equity456.23
Liabilities & Stockholder's Equity511.25
4 historic quarters locked

Sign in to unlock the full Celldex Therapeutics inc balance sheet history.

About Celldex Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-091984

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.